Australia could beat the US to register the world’s first prescription CBD pain tablet after an Australian pharmaceutical firm completed clinical trials and lodged its TGA application.
Australian firm Promethean BioPharma has completed clinical trials for a new cannabidiol (CBD pain relief tablet and submitted the medicine to Theraputic Goods Administration (TGA) for registration,a process which is expected to take about six months.
The company’s scientists have developed a cannabis-based medicine which contains zero THC, which is the chemical element that causes the drug’s high sensation. The use of cannabis for medicinal purpose has long been a controversial issue, largely due to the presence of the THC chemical. Concerns include that some users have developed mental health issues and have side effects such as loss of co-ordination.
Should the ground-breaking medicine receive TGA registration, it would mean it could hit overseas pharmacies, hospital wards and GP surgeries and remove current red tape domestically.
Should this happen, it would become the world’s first prescription CBD tablet for pain medication – with Australia beating off America in the race to get the product registered first.
Promethean BioPharma chief executive Peter Comerford said that the eventual goal would be for the tablet to be available over the counter and treated no differently to paracetamol or ibuprofen.
“It is time for cannabis to grow up if it wants to be a medicine and this is an asbolutely huge step,” Mr Comerford told NewsWire.
“This would be a major step for Australia. We have all the resources to grow the plant, process it, turn it into a clinically tested tablet and supply the world with it, all in Australia.”
While the product can already be sold and prescribed under certain conditions, TGA registration would make it the first of its kind to be a registered prescription medicine.
The eight-week clinical trial involved 155 adults using the either the tablet or a placebo for a period of four weeks, three of whom entered the trial with pre-existing heart rhythm risks. Mr Comerford said the company was encouraged by the safety findings observed during the trial, including among those with pre-existing heart-rhythm risk factors.
According to the company, around 10 per cent of the participants were described as “high responders” experiencing meaningful pain relief from week one, which was reported to continue throughout the four-week treatment period.
The company also hopes Australian registration could support its plans to seek regulatory approval in overseas markets including the United Kingdom, Canada and Germany.
Australians can already access certain unapproved medicinal cannabis products on prescription through established TGA access pathways, subject to applicable requirements. The indications for which this particular medicine may ultimately be registered will be determined through the TGA registration process.
GPs are able to prescribe the new drug providing they meet a host of conditions. However, TGA registration would remove layers of red tape, making it easier for GPs to prescribe it.
“What happens next is bigger than us,” Mr Comerford said.
“If the TGA agrees to fast track this, Australia becomes the first country anywhere to register a CBD tablet for pain and the National Reconstruction Fund Corporation has already told us it’s ready to back the next stage once we get there.
“That is a serious vote in confidence in Australian science staying Australian owned,” he said.
